Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 13  |  Issue : 51  |  Page : 499-504

Antihyperglycemic activity of Caralluma fimbriata: An In vitro approach


Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha University, Chennai, Tamil Nadu, India

Correspondence Address:
Roy Anitha
Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha University, Chennai - 600 077, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/pm.pm_59_17

Rights and Permissions

Background: An increase in prevalence of diabetes mellitus necessitates the need to develop new drugs for its effective management. Plants and their bioactive compounds are found to be an alternative therapeutic approach. Caralluma fimbriata, used in this study, is well known for its various biological effects. Objective: The present study was designed to investigate the antihyperglycemic effect of the ethanolic leaf extract of C. fimbriata. Materials and Methods: Different concentrations (1–1000 μ g/mL) of the ethanolic leaf extract of C. fimbriata were subjected to alpha-amylase and alpha-glucosidase inhibitory assay with acarbose as control. Cytotoxicity was assessed by 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. Glucose uptake assay was performed on L6 myotubes using the extract in 1 μ g–100 μ g/mL, using metformin and insulin as control. Results: The C. fimbriata extract showed potent inhibitory activity on enzymes of glucose metabolism in a dose-dependent manner. The maximum alpha-amylase inhibitory effect was 77.37% ± 3.23% at 1000 μ g/mL with an IC50value of 41.75 μ g/mL and alpha-glucosidase inhibitory effect was 83.05% ± 1.69% at 1000 μ g/mL with an IC50value of 66.71 μ g/mL. The maximum glucose uptake was found to be 66.32% ± 0.29% for the Caralluma extract at 100 μ g/mL and that of metformin (10 μ g/mL) was 74.44% ± 1.72% and insulin (10 μ M) 85.55% ± 1.14%. The extract was found to be safe as the IC50of extract and metformin was found to be ≥1000 μ g/mL and ≥1000 μ M, respectively, in the cell line tested. Conclusion: The study concludes that C. fimbriata has promising antihyperglycemic activity. Abbreviations used: GLUT: Glucose transporter; MTT: 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2623    
    Printed47    
    Emailed0    
    PDF Downloaded191    
    Comments [Add]    

Recommend this journal